Brainstorm Cell Therapeutics Announces COO Resignation

  • Investing.com
Brainstorm Cell Therapeutics Announces COO Resignation

On May 18, 2023, David Setboun, PhD, MBA, Executive Vice President and Chief Operating Officer of Brainstorm Cell Therapeutics (NASDAQ: BCLI ), notified the Company of his decision to resign from his role effective as of May 31, 2023 to pursue another opportunity. Dr. Setboun’s decision to resign was not due to
any disagreement with the Company on any matter, or relating to its operations, policies, or practices.

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or

100